Your browser doesn't support javascript.
loading
Levels of small extracellular vesicles in patients treated with hyperbaric oxygenation.
Siewiera, Jacek; Smolenski, Michal; Jermakow, Natalia; Kot, Jacek; Reichert, Torsten E; Miskiewicz, Piotr; Zareba, Lukasz; Cyran, Anna; Szczepanski, Miroslaw J; Ludwig, Nils.
Afiliación
  • Siewiera J; Department of Hyperbaric Medicine, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
  • Smolenski M; Department of Biochemistry, Medical University of Warsaw, Warsaw, Poland.
  • Jermakow N; Department of Hyperbaric Medicine, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
  • Kot J; National Centre for Hyperbaric Medicine, Institute of Maritime and Tropical Medicine, Medical University of Gdansk, Gdansk, Poland.
  • Reichert TE; Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, Regensburg, Germany.
  • Miskiewicz P; Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland.
  • Zareba L; Department of Biochemistry, Medical University of Warsaw, Warsaw, Poland.
  • Cyran A; Department of Biochemistry, Medical University of Warsaw, Warsaw, Poland.
  • Szczepanski MJ; Department of Biochemistry, Medical University of Warsaw, Warsaw, Poland.
  • Ludwig N; Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, Regensburg, Germany.
Arch Med Sci ; 20(2): 476-484, 2024.
Article en En | MEDLINE | ID: mdl-38757025
ABSTRACT

Introduction:

Hyperbaric oxygen (HBO2) therapy involves the inhalation of pure oxygen in a pressure chamber under increased ambient pressure. Recent research indicates that circulating small extracellular vesicles (sEVs) play important roles in human physiology and pathology. Therefore, the objective of this pilot study was to monitor the impact of HBO2 therapy on the levels of circulating sEVs in the serum of patients with necrotizing soft-tissue infections (NSTI), aseptic bone necrosis (ABN) or idiopathic sudden sensory neural hearing loss (ISSNHL). Material and

methods:

Serum-derived sEVs were isolated and quantified in 80 patients before and after HBO2 therapy applied for NSTI, ISSNHL and ABN patients as well as in normal controls who received neither HBO2 therapy nor steroids.

Results:

We observed a significant increase of circulating sEVs in patients with ISSNHL after HBO2 therapy (p < 0.05), as well as significantly elevated levels of sEVs after HBO2 therapy compared to patients with NSTI (p < 0.05) and ABN (p < 0.01).

Conclusions:

The increase in the levels of sEVs in ISSNHL may be evidence for both the intended reduction of inflammation as a result of steroid therapy and the inhibitory effect of oxidative stress induced by HBO2 therapy. Thus, sEVs released during HBO2 therapy might play an important biological role in mediating the response to therapy and might be a promising approach to gain further insights into the therapeutic efficacy of HBO2 therapy.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Arch Med Sci Año: 2024 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Polonia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Arch Med Sci Año: 2024 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Polonia